These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
115 related items for PubMed ID: 9337951
1. Incidence and risk factors for severe tardive dyskinesia in older patients. Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV. Br J Psychiatry; 1997 Aug; 171():148-53. PubMed ID: 9337951 [Abstract] [Full Text] [Related]
6. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Harris MJ, Panton D, Caligiuri MP, Krull AJ, Tran-Johnson TK, Jeste DV. Psychopharmacol Bull; 1992 Sep; 28(1):87-92. PubMed ID: 1609047 [Abstract] [Full Text] [Related]
7. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. J Am Geriatr Soc; 1999 Jun; 47(6):716-9. PubMed ID: 10366172 [Abstract] [Full Text] [Related]
8. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Sachdev P. Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837 [Abstract] [Full Text] [Related]
9. A prospective study of tardive dyskinesia in Japan. Inada T, Ohnishi K, Kamisada M, Matsuda G, Tajima O, Yanagisawa Y, Hashiguchi K, Shima S, Oh-e Y, Masuda Y. Eur Arch Psychiatry Clin Neurosci; 1991 Jun; 240(4-5):250-4. PubMed ID: 1675874 [Abstract] [Full Text] [Related]
11. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Dolder CR, Jeste DV. Biol Psychiatry; 2003 Jun 15; 53(12):1142-5. PubMed ID: 12814866 [Abstract] [Full Text] [Related]
13. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Acta Psychiatr Scand; 1993 Jan 15; 87(1):29-36. PubMed ID: 8093821 [Abstract] [Full Text] [Related]
14. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Am J Psychiatry; 1998 Apr 15; 155(4):565-7. PubMed ID: 9546009 [Abstract] [Full Text] [Related]
15. Adolescents on neuroleptic medication: is this population at risk for tardive dyskinesia? McDermid SA, Hood J, Bockus S, D'Alessandro E. Can J Psychiatry; 1998 Aug 15; 43(6):629-31. PubMed ID: 9729692 [Abstract] [Full Text] [Related]
16. Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables. Mukherjee S, Rosen AM, Cardenas C, Varia V, Olarte S. Arch Gen Psychiatry; 1982 Apr 15; 39(4):466-9. PubMed ID: 6121547 [Abstract] [Full Text] [Related]
17. Tardive dyskinesia: a review. Latimer PR. Can J Psychiatry; 1995 Sep 15; 40(7 Suppl 2):S49-54. PubMed ID: 8564917 [Abstract] [Full Text] [Related]
18. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. Morgenstern H, Glazer WM, Gibowski LD, Holmberg S. J Chronic Dis; 1987 Sep 15; 40(4):319-27. PubMed ID: 2881941 [Abstract] [Full Text] [Related]
19. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Yassa R, Nastase C, Dupont D, Thibeau M. Am J Psychiatry; 1992 Sep 15; 149(9):1206-11. PubMed ID: 1354413 [Abstract] [Full Text] [Related]